414910-19-3

Usage

Uses

Used in Pharmaceutical Research and Drug Development:
1(2H)-Pyridinecarboxylic acid, 2-(4-fluorophenyl)-3,4-dihydro-4-oxo-, phenylmethyl ester is used as a chemical compound in pharmaceutical research and drug development for its potential antiviral, antifungal, and anti-inflammatory properties.
Used in Antiviral Applications:
In the medical industry, 1(2H)-Pyridinecarboxylic acid, 2-(4-fluorophenyl)-3,4-dihydro-4-oxo-, phenylmethyl ester is used as an antiviral agent to study its potential in combating viral infections.
Used in Antifungal Applications:
In the medical industry, 1(2H)-Pyridinecarboxylic acid, 2-(4-fluorophenyl)-3,4-dihydro-4-oxo-, phenylmethyl ester is used as an antifungal agent to study its potential in treating fungal infections.
Used in Anti-Inflammatory Applications:
In the medical industry, 1(2H)-Pyridinecarboxylic acid, 2-(4-fluorophenyl)-3,4-dihydro-4-oxo-, phenylmethyl ester is used as an anti-inflammatory agent to study its potential in reducing inflammation and related conditions.
Used in Neurodegenerative Disease Treatment:
In the medical industry, 1(2H)-Pyridinecarboxylic acid, 2-(4-fluorophenyl)-3,4-dihydro-4-oxo-, phenylmethyl ester is used as a potential treatment for neurodegenerative diseases such as Alzheimer's and Parkinson's due to its ability to inhibit the production of cytokines involved in the immune response.

Upstream product

• 460-00-4 1-Bromo-4-fluorobenzene 
• 620-08-6 4-methoxypyridine 
• 501-53-1 benzyl chloroformate 
• 352-13-6 4-flourophenylmagnesium bromide 

Relevant academic research and scientific papers

Discovery of BAY-298 and BAY-899: Tetrahydro-1,6-naphthyridine-Based, Potent, and Selective Antagonists of the Luteinizing Hormone Receptor Which Reduce Sex Hormone Levels in Vivo

The human luteinizing hormone receptor (hLH-R) is a member of the glycoprotein hormone family of G-protein-coupled receptors (GPCRs), activated by luteinizing hormone (hLH) and essentially involved in the regulation of sex hormone production. Thus, hLH-R

4-PIPERIDIN-N-(PYRIMIDIN-4-YL)CHROMAN-7-SULFONAMIDE DERIVATIVES AS SODIUM CHANNEL INHIBITORS

The invention provides 4-piperidin-chroman-7-sulfonamide derivatives and salts thereof that are sodium channel modulators, as well as compositions containing such a compound or salt and therapeutic methods for using such a compound, salt, or composition.

THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF

The invention provides a compound of formula: or a salt thereof, wherein the variables RAA, n, ring A, ring B, R1a, R1b, R2, R3, R4, R5, R6, R7, R8, and R9 have the meaning as described herein, and compositions containing such compounds and methods for using such compounds and compositions.

BENZOXAZEPINES AS INHIBITORS OF P13K/MTOR AND METHODS OF THEIR USE AND MANUFACTURE

The invention is directed to Compounds of Formula I: and pharmaceutically acceptable salts or solvates thereof, as well as methods of making and using the compounds. 9936396.1

BENZOXAZEPINES AS INHIBITORS OF MTOR AND METHODS OF THEIR USE AND MANUFACTURE

The invention is directed to inhibitors of mTOR and pharmaceutically acceptable salts or solvates thereof, as well as methods of using them. The inhibitors are generally of structural formula wherein the combination of R1 and R2 are

BENZOXAZEPINES AS INHIBITORS OF PI3K/m TOR AND METHODS OF THEIR USE AND MANUFACTURE

The invention is directed to Compounds of Formula (I): the invention provides compounds that inhibit, regulate, and/or modulate P13K and/or mTOR that are useful in the treatment of hyperproliferative diseases, such as cancer, in mammals. This invention al

Synthesis of C2-symmetric trans-2,6-diarylpiperidinones via aryl cuprate addition: an unexpected stereochemical outcome

An efficient procedure for the preparation of trans-2,6-diaryl piperidinones has been developed. Addition of aryl Grignard reagents to 2-aryl dihydropyridones under catalytic copper promoted conditions generates the trans isomer exclusively, an unprecedented stereochemical event. The X-ray structures of both starting material and product have been solved and shed light on the steric constraints and substrate geometry leading to the observed product. The reaction conditions tolerate a variety of aromatic nucleophiles to generate C2-symmetric products in good overall yields.

Chemical compounds

Formula (1) wherein R represents a halogen atom or a C1-4 alkyl group; R1 represents a C1-4 alkyl group; R2 represents hydrogen or a C1-4 alkyl group; R3 represents hydrogen, or a C1-4 alkyl group; R4 represents a trifluorometyl group; R5 represents hydrogen, a C1-4 alkyl group or C(0)R6; R6? represents C1-4 alkyl, C3-7 cycloalkyl, NH(C1-4 alkyl) or N(C1-4alkyl)2; m is zero or an integer from 1 to 3; n is an integer from 1 to 3 and pharmaceutically acceptable salts and solvates thereof; to processes for their preparation and their use in the treatment of conditions mediated bytachykinins.

NOVEL PIPERIDINE COMPOUND

The present invention provides a novel piperidine compound of the formula [I]: wherein Ring A represents an optionally substituted benzene ring, Ring B represents an optionally substituted benzene ring, R1 represents an optionally substituted alkyl group, an optionally substituted hydroxyl group, etc., or a group of the formula: (a) wherein R11 and R12 are the same or different, and each represents hydrogen atom, a substituted carbonyl group, a substituted sulfonyl group, an optionally substituted alkyl group, etc., R2 represents hydrogen atom, etc., Z represents oxygen atom or a group represented by -N(R3)-, R3 represents hydrogen atom or an alkyl group, etc., R4 represents hydrogen atom or an alkyl group, etc.,or a pharmaceutically acceptable salt thereof.